Tag Archives: corporate venture capital

RESI Boston Summer 2018 Panel Announcement: Corporate Venture Capital

24 May

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Reza Halse, President, MRL Ventures, this panel will feature:

By registering for RESI Boston, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

RESI on MaRS Panel Announcement: Corporate Venture Capital

22 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical and biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation – an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:

  • Marian Nakada, VP of Venture Investing, Johnson & Johnson
  • Jens Eckstein, President, SR One
  • Richard Osborn, Managing Partner, TELUS Ventures
  • Tom Gibbs, Director, Debiopharm Innovation Fund

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

RESI San Diego Panel: Corporate Venture Capital

1 Jun

By Lucy Parkinson, Director of Research, LSN

Corporate venture capital funds have been a key pillar of the life science investment community for some time, and at LSN we’ve seen these groups evolving on strategy to keep up with an increasingly competitive investor marketplace. While many pharma firms still use corporate VC as a strategic vehicle for filling pipelines, these firms are increasingly collaborative and keen to be seen as aligned with the interests of entrepreneurs and other investors, as well as those of their parent companies.

At RESI, a panel of 5 top corporate VCs from around the world will explain how their group makes strategic investments in early stage companies, and how a corporate VC relationship can help a startup company get ahead in development and strategic relationships.

Moderated by Rajeev Dadoo (Partner, SR One), the participants are:

RESI on MaRS Panel Announcement: Corporate Venture Capital

2 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the second time and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by John Gustofson, Senior Director, Abbvie Ventures, this panel will feature:

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

3 Nov

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017

Redefining Early Stage Investments (RESI) Conference: Corporate VCs & Strategic Investment Panel

7 Jan

By Christine A. Wu, Research Analyst, LSN

chrsitine

At LSN’s RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.

In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.

Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:

  • Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
  • Geeta Vemuri, Vice President, Head, Baxalta Ventures
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Ilan Zipkin, Senior Investment Director, Takeda Ventures

If you’re a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before it’s too late.

RESI-San-Francisco-2016

Hot Life Science Investor Mandate 2: CVC of Large Pharma Looking Opportunistically for Life Science Investments

17 Jul

The Corporate Venture Capital arm of a Global Pharmaceutical company provides seed and venture capital to development stage companies within life science and biotechnology. The firm provides pre-seed grants and seed investments to early-stage life science projects in Scandinavia. The firm’s venture investment activities are structured as an open evergreen fund. The firm invests at any stage of development – seed, venture, and growth. The firm also makes late-stage investments in public/private companies with a positive cash flow. The firm can allocate up to $30M per company, but generally allocates between $5M to $20M. The firm seeks companies that are based in North America and Europe. The firm has no current mandate for the number of allocations it plans to make and will evaluate relevant opportunities as they surface.

The firm is opportunistic in the life sciences space. The firm specifically focuses on companies that specialize in the development of novel drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology.  The firm is open to all technology and indication areas within these sectors. 

The firm seeks company ownership in return for its seed investments and influential equity ownership for late-stage investments. The firm considers both pre-revenue and revenue generating private and public companies.  The firm is generally opportunistic with the management team, but highly prefers an experienced and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: